I can understand that AHZ is still at the speculative end of the...

I can understand that AHZ is still at the speculative end of the ASX but in terms of operational progression and sheer potential based on the amount of clinical papers validating the use of Cardiocel, one would somewhat be disappointed with the share price performance so far. There is also the willingness of holders to part with their script at such low levels which I find disconcerting.
Compared the performance of AHZ with PSY, also in the spec space, AHZ management has done a poor job in cap raising and bringing the shareholders with them on the journey forward.
PSY doesn't even have a commercially viable product currently and yet its is able to get its shareholders' base excited despite a recent cap raising at a massive premium over the VWAP period.